{ "schemaVersion": 2, "eyebrow": "Emergency Psychiatry", "title": "Neuroleptic Malignant Syndrome", "summary": "Treat suspected neuroleptic malignant syndrome as a medical emergency: stop dopamine-blocking drugs, stabilize hyperthermia and rhabdomyolysis, exclude mimics, and escalate to intensive care when autonomic, respiratory, renal, or consciousness abnormalities are present.", "seoDescription": "Point-of-care diagnosis and management of neuroleptic malignant syndrome, including emergency stabilization, differential diagnosis, pharmacotherapy, and rechallenge.", "clinicalQuestion": "How should clinicians recognize, stabilize, treat, and safely reconsider antipsychotic therapy after suspected neuroleptic malignant syndrome?", "specialty": "Emergency Medicine and Psychiatry", "audience": "U.S. physicians and medical trainees", "tags": [ "neuroleptic malignant syndrome", "NMS", "antipsychotic adverse effect", "hyperthermia", "rigidity", "rhabdomyolysis", "bromocriptine", "dantrolene" ], "keyTakeaways": [ "Suspect NMS after exposure to an antipsychotic or another dopamine-blocking drug when hyperthermia, generalized rigidity, altered mental status, and autonomic instability cluster; creatine kinase elevation, myoglobinuria, and acute kidney injury support severity assessment. [1][2][3][21]", "Immediately discontinue the precipitating antipsychotic and nonessential concomitant drugs, initiate active cooling, intravenous hydration, electrolyte correction, and cardiorespiratory monitoring; severe presentations generally require ICU-level care. [1][21][23][24]", "Do not anchor on NMS before excluding infection, untreated extrapyramidal syndromes, central anticholinergic toxicity, heat stroke, drug fever, primary CNS disease, serotonin syndrome, and malignant catatonia. [1][2][3][9][12]", "For moderate or severe NMS, bromocriptine, dantrolene, and benzodiazepines are used on case-based evidence; electroconvulsive therapy is a treatment option for refractory illness or when catatonia is a major competing diagnosis. [21][23][24]", "If antipsychotic reintroduction is unavoidable after recovery, use a lower-D2-potency agent such as quetiapine or clozapine, titrate very gradually, and monitor closely; reported recurrence risk is approximately 10% to 40%. [23]" ], "sections": [ { "id": "recognition-and-triage", "eyebrow": "Emergency Recognition", "heading": "When to treat as suspected NMS", "intro": "Management begins before diagnostic certainty because progression can include rhabdomyolysis, renal failure, dysrhythmia, and respiratory compromise.", "paragraphs": [ "Treat the syndrome as presumptive NMS when a patient exposed to an antipsychotic develops the core cluster of hyperthermia, diffuse muscle rigidity, altered mental status, and autonomic instability. Irregular or labile blood pressure, tachycardia, diaphoresis, and dysrhythmia are characteristic autonomic findings; elevated creatine kinase, myoglobinuria, rhabdomyolysis, and acute renal failure are important complications rather than required diagnostic features. [1][2][3][21]", "The temporal relationship to dopamine blockade is a major discriminator. NMS is typically reported within 24 to 72 hours of exposure and is uncommon after 2 weeks, although depot formulations can extend the exposure window. Do not exclude NMS because the agent is an atypical antipsychotic: paliperidone, olanzapine, quetiapine, and clozapine labeling each describes NMS. [1][2][3][5][9]", "Escalate immediately to a monitored or ICU setting for hyperthermia with rigidity, delirium or reduced consciousness, autonomic lability, significant creatine kinase elevation, myoglobinuria, renal dysfunction, respiratory compromise, or inability to maintain airway protection. ICU care is used to provide aggressive hydration, electrolyte correction, cooling, and cardiorespiratory support. [21][22][23][24]" ], "bullets": [ "Obtain a complete medication timeline: antipsychotic initiation, dose escalation, depot administration, PRN injections, antiemetics with dopamine blockade such as metoclopramide, and recent medication withdrawal. [23]", "Perform repeated examinations for lead-pipe rigidity, tremor, dystonia, bradykinesia, dysphagia, dysarthria, trismus, altered consciousness, and fluctuating blood pressure or pulse. [9]", "Avoid physical restraint when possible; benzodiazepines are preferred for agitation in NMS because restraint may worsen exertional heat generation and muscle injury. [23]" ], "subsections": [], "table": { "caption": "Immediate triage actions for suspected neuroleptic malignant syndrome. [1][21][23][24]", "columns": [ "Priority", "Action", "Clinical purpose" ], "rows": [ [ "Remove trigger", "Stop the suspected antipsychotic and other nonessential drugs immediately. [1][23]", "Prevents continued dopamine blockade and permits diagnostic reassessment." ], [ "Stabilize", "Institute active cooling, intravenous hydration, electrolyte correction, and cardiorespiratory monitoring. [21][23][24]", "Limits hyperthermia, rhabdomyolysis, renal injury, and autonomic complications." ], [ "Escalate", "Transfer to higher-acuity or ICU care when medical severity warrants. [21][23][24]", "Enables airway, hemodynamic, renal, and respiratory support." ], [ "Investigate", "Assess for infection, CNS pathology, toxicologic syndromes, heat illness, and catatonia while treating presumptively. [1][2][3][12]", "NMS is a diagnosis of exclusion and mimics require different definitive therapy." ] ] } }, { "id": "diagnostic-workup", "eyebrow": "Diagnostic Branching", "heading": "Confirm the syndrome pattern and exclude high-consequence mimics", "intro": "No single laboratory finding establishes NMS; use medication exposure, serial examination, complications, and targeted exclusion of alternatives.", "paragraphs": [ "Obtain serial temperature, heart rate, blood pressure, respiratory rate, oxygen saturation, mental-status assessments, and focused neuromuscular examinations. Check creatine kinase and leukocyte count as supportive laboratory measures, and evaluate for myoglobinuria and acute renal injury when rhabdomyolysis is suspected. [1][2][24]", "Use the consensus hyperthermia threshold of temperature greater than 100.4°F (38.0°C) as a diagnostic criterion, but do not defer treatment when the clinical pattern and exposure history are compelling before full hyperthermia develops. Rigidity may precede hyperthermia, and atypical presentations have been described with incomplete expression of the classic features. [17][8][10]", "The diagnostic task is not merely to label fever and elevated creatine kinase as NMS. FDA labeling specifically directs clinicians to identify serious medical illness, including pneumonia and systemic infection, and untreated or inadequately treated extrapyramidal symptoms. Consider central anticholinergic toxicity, heat stroke, drug fever, and primary CNS pathology in parallel. [1][2][3]" ], "bullets": [ "Screen for infectious illness when fever, leukocytosis, pulmonary findings, meningismus, or focal symptoms suggest pneumonia, sepsis, or CNS infection rather than medication toxicity. [1][2][3]", "Pursue neuroimaging and other CNS-directed evaluation when focal neurologic findings, seizure, severe headache, trauma, or a nonmedication explanation suggests primary CNS pathology. [1][2][3]", "Review serotonergic, anticholinergic, and dopaminergic medications; serotonin syndrome and central anticholinergic toxicity remain important competing toxicologic diagnoses. [1][2][3][18]" ], "subsections": [ { "heading": "Malignant catatonia versus NMS", "paragraphs": [ "Malignant catatonia can produce dysautonomia, hyperthermia, altered consciousness, rigidity, and laboratory abnormalities overlapping with NMS. A catatonic syndrome that precedes dopamine-blocker exposure or worsens after antipsychotic administration should keep malignant catatonia high in the differential and prompt coordinated psychiatric-critical care management. [9][12]", "When catatonia is suspected, a parenteral lorazepam challenge of 1 to 2 mg can be used; continued benzodiazepine treatment is reasonable when a response occurs. Electroconvulsive therapy has been used for treatment-refractory NMS and may be especially relevant when malignant catatonia remains a major diagnostic possibility. [24][23]" ], "bullets": [] } ], "table": { "caption": "High-yield differentiation of NMS from competing hyperthermic syndromes. [1][2][3][9][12][18]", "columns": [ "Branch", "Finding that shifts probability", "Immediate next action" ], "rows": [ [ "NMS", "Recent dopamine-blocking drug exposure with hyperthermia, rigidity, altered mental status, autonomic instability, and possible CK elevation or myoglobinuria. [1][2][3][21]", "Stop implicated drugs; cool, hydrate, monitor, and evaluate complications. [1][21][23]" ], [ "Malignant catatonia", "Catatonic syndrome with hyperthermia and dysautonomia; symptoms may progress with dopamine antagonists and overlap with NMS. [12]", "Use psychiatric-critical care collaboration; consider lorazepam challenge and ECT when indicated. [23][24]" ], [ "Serotonin syndrome", "Serotonergic toxic exposure is a competing explanation for hyperthermia and autonomic instability. [18]", "Stop serotonergic agents and direct management to the alternative toxidrome after focused neuromuscular examination and medication review." ], [ "Central anticholinergic toxicity", "Anticholinergic exposure provides a competing toxicologic explanation for fever and altered mental status. [1][2][3]", "Stop contributing agents and manage as anticholinergic toxicity while excluding NMS." ], [ "Infection, heat stroke, drug fever, CNS disease", "Systemic infectious findings, environmental heat exposure, fever temporally unrelated to dopamine blockade, or focal CNS signs shift away from NMS. [1][2][3]", "Obtain targeted infectious, environmental, toxicologic, and neurologic evaluation without delaying stabilization." ] ] } }, { "id": "acute-management", "eyebrow": "Acute Treatment", "heading": "Stabilize first, then add syndrome-directed pharmacotherapy by severity", "intro": "Medication treatment is adjunctive to withdrawal of the trigger and intensive supportive care.", "paragraphs": [ "Immediately discontinue all antipsychotic drugs and other nonessential concurrent medications. Begin active cooling for hyperthermia, aggressive intravenous hydration for rhabdomyolysis risk, correction of electrolyte abnormalities, and cardiorespiratory support. Address coexisting serious medical illness with its specific therapy rather than attributing every abnormality to NMS. [1][21][23][24]", "Use benzodiazepines for agitation, delirium, or possible catatonia. Lorazepam 1 to 2 mg IM or IV every 4 to 6 hours is described for mild or early NMS; diazepam 10 mg IV every 8 hours is another reported regimen. Monitor for sedation and hypotension. [21]", "For moderate NMS, add a dopamine-enhancing strategy when supportive care and benzodiazepines are insufficient. Bromocriptine 2.5 mg by nasogastric tube every 8 to 12 hours may be titrated to a maximum of 45 mg/day; amantadine 200 to 400 mg/day in 2 or 3 divided doses is an alternative. Bromocriptine can cause hypotension, gastrointestinal adverse effects, and psychosis; amantadine can cause orthostatic hypotension and agitation. [21][24]", "For severe rigidity and hyperthermia, dantrolene is commonly used with supportive care and bromocriptine. Reported regimens include an IV 1 mg/kg bolus followed by 1 mg/kg IV every 6 hours; dosing has varied in published cases, reflecting the absence of consistent treatment guidelines. [22][23][24]", "Consider ECT when NMS is refractory to withdrawal, supportive care, and pharmacologic treatment, or when malignant catatonia remains likely and requires definitive treatment. This decision requires psychiatric, anesthesia, and critical-care coordination in medically unstable patients. [23][12]" ], "bullets": [ "Monitor urine output, creatine kinase trend, renal function, electrolytes, temperature, mental status, and hemodynamic status during active illness because these parameters track rhabdomyolysis, renal injury, and autonomic progression. [1][21][24]", "Use enteral access when needed for bromocriptine or amantadine in patients unable to take oral therapy; bromocriptine administration by nasogastric tube is specifically described. [21][22]", "Do not resume dopamine-blocking agents during the acute episode; reassess the underlying psychiatric or neurologic indication only after clinical recovery. [1][23]" ], "subsections": [], "table": { "caption": "Severity-directed adjunctive pharmacotherapy for NMS; all regimens accompany trigger withdrawal and aggressive supportive care. [21][22][23][24]", "columns": [ "Clinical setting", "Adjunctive option", "Source-supported regimen and key caution" ], "rows": [ [ "Mild or early NMS; agitation or possible catatonia", "Lorazepam", "1 to 2 mg IM or IV every 4 to 6 hours; monitor sedation and hypotension. [21]" ], [ "Alternative benzodiazepine regimen", "Diazepam", "10 mg IV every 8 hours. [21]" ], [ "Moderate NMS", "Bromocriptine", "2.5 mg by nasogastric tube every 8 to 12 hours; maximum 45 mg/day. Hypotension and psychosis are relevant risks. [21]" ], [ "Moderate NMS alternative", "Amantadine", "200 to 400 mg/day in 2 or 3 divided doses; monitor for orthostatic hypotension and agitation. [21][24]" ], [ "Severe rigidity or hyperthermia", "Dantrolene", "A reported regimen is 1 mg/kg IV bolus followed by 1 mg/kg IV every 6 hours; case-based dosing varies. [22]" ], [ "Refractory NMS or strong malignant catatonia concern", "ECT", "Used successfully in treatment-refractory NMS; coordinate psychiatric and critical-care care. [23][12]" ] ] } }, { "id": "recovery-and-rechallenge", "eyebrow": "After Recovery", "heading": "Reconsider antipsychotic treatment only when the indication outweighs recurrence risk", "intro": "Rechallenge is individualized and should follow complete clinical recovery and resolution of acute medical instability.", "paragraphs": [ "Before rechallenge, document the suspected trigger, exposure timing, dose changes, coadministered dopamine-blocking agents, acute complications, and alternative diagnoses considered. Correct reversible contributors such as dehydration, infection, electrolyte disturbance, and untreated extrapyramidal symptoms before again exposing the patient to dopamine blockade. [1][2][3][23]", "If antipsychotic treatment remains necessary, delay reintroduction as long as clinically feasible after resolution; a longer interval from recovery to rechallenge is associated with lower recurrence risk. Reported recurrence risk is approximately 10% to 40%, so the restart plan should explicitly balance psychiatric relapse risk against recurrent NMS. [23]", "Select a lower-D2-potency antipsychotic such as quetiapine or clozapine, begin at a very low dose, titrate gradually, and monitor closely for recurrent rigidity, fever, autonomic change, mental-status deterioration, and creatine kinase elevation when clinically indicated. Atypical agents are not risk-free: NMS is described in labeling for quetiapine, olanzapine, paliperidone, and clozapine. [23][1][2][3][5]" ], "bullets": [ "Avoid repeat exposure to the likely offending agent when an effective alternative exists. [23]", "Use the minimum necessary antipsychotic dose and avoid rapid titration during rechallenge. [23]", "Consider ECT as a bridge or longer-term strategy when psychosis requires treatment but antipsychotic rechallenge presents unacceptable risk. [23]" ], "subsections": [], "table": { "caption": "Structured antipsychotic rechallenge after NMS. [23]", "columns": [ "Step", "Decision rule", "Implementation" ], "rows": [ [ "Confirm need", "Rechallenge only when ongoing psychosis or another indication requires antipsychotic therapy.", "Reassess non-antipsychotic and ECT options first. [23]" ], [ "Reduce recurrence risk", "Longer delay after syndrome resolution is associated with less recurrence.", "Wait until clinical recovery and medical stability; individualize timing. [23]" ], [ "Choose agent", "Prefer lower-D2-potency treatment when antipsychotic therapy is necessary.", "Consider quetiapine or clozapine rather than a higher-potency D2 blocker. [23]" ], [ "Titrate and monitor", "Recurrence is reported in roughly 10% to 40%.", "Use very gradual titration and close surveillance for recurrent NMS features. [23]" ] ] } }, { "id": "special-populations-and-exceptions", "eyebrow": "Clinical Exceptions", "heading": "Recognize dopamine-withdrawal and neurologic contexts", "intro": "An NMS-like syndrome is not limited to newly prescribed antipsychotics.", "paragraphs": [ "In Parkinson disease and other extrapyramidal disorders, abrupt withdrawal of levodopa or other dopaminergic therapy can produce an NMS-like syndrome. In a rigid, febrile, autonomically unstable patient with parkinsonism, establish whether dopaminergic medication was interrupted as well as whether a dopamine blocker was introduced. [14]", "In pediatric anti-NMDA receptor encephalitis, antipsychotics may worsen dyskinesia or induce NMS; severe behavioral dysregulation with dyskinesia and autonomic instability should therefore prompt reassessment for autoimmune encephalitis and prioritization of treatment for the underlying disease. [15]", "For patients with dementia-related psychosis, note that antipsychotic product labeling also carries safety concerns regarding increased mortality and cerebrovascular adverse events; NMS recognition should not obscure medication-specific risk-benefit reassessment after recovery. [2][3]" ], "bullets": [], "subsections": [], "table": { "caption": "Contexts that should alter the medication history in suspected NMS. [14][15]", "columns": [ "Clinical context", "Medication question", "Implication" ], "rows": [ [ "Parkinson disease or parkinsonism", "Was levodopa or another dopaminergic regimen recently stopped or interrupted? [14]", "Consider dopamine-withdrawal NMS-like syndrome." ], [ "Pediatric dyskinesia with psychiatric symptoms", "Could anti-NMDA receptor encephalitis be present, and was an antipsychotic given? [15]", "Antipsychotics may worsen dyskinesia or induce NMS; prioritize assessment and treatment of the underlying encephalitis." ], [ "Dementia-related psychosis", "Is ongoing antipsychotic exposure justified after recovery? [2][3]", "Reassess cerebrovascular and mortality risks in addition to NMS recurrence risk." ] ] } } ], "faq": [], "references": [ { "number": 1, "title": "This label may not be the latest approved by FDA. For current ...", "detail": "www.accessdata.fda.gov", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021999s005s008lbl.pdf", "authors": "www.accessdata.fda.gov", "host": "www.accessdata.fda.gov" }, { "number": 2, "title": "1 This label may not be the latest approved by FDA. For ...", "detail": "www.accessdata.fda.gov", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022173s034lbl.pdf", "authors": "www.accessdata.fda.gov", "host": "www.accessdata.fda.gov" }, { "number": 3, "title": "quetiapine fumarate extended-release tablets", "detail": "www.accessdata.fda.gov", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/090482Orig1s000lbl.pdf", "authors": "www.accessdata.fda.gov", "host": "www.accessdata.fda.gov" }, { "number": 4, "title": "Reference ID: 2906104 - accessdata.fda.gov", "detail": "www.accessdata.fda.gov", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021999s017lbl.pdf", "authors": "www.accessdata.fda.gov", "host": "www.accessdata.fda.gov" }, { "number": 5, "title": "CLOZARIL- clozapine tablet TYA Pharmaceuticals", "detail": "dailymed.nlm.nih.gov", "url": "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setId=0cf63b13-48b2-4b07-b241-617725b52f6b", "authors": "dailymed.nlm.nih.gov", "host": "dailymed.nlm.nih.gov" }, { "number": 6, "title": "Neuroleptic malignant syndrome! | The BMJ", "detail": "www.bmj.com", "url": "https://www.bmj.com/rapid-response/2011/10/30/neuroleptic-malignant-syndrome", "authors": "www.bmj.com", "host": "www.bmj.com" }, { "number": 7, "title": "Neuroleptic Malignant Syndrome - ScienceDirect", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/abs/pii/B9780125897624500839", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com" }, { "number": 8, "title": "Major symptoms and differential diagnosis of neuroleptic malignant syndrome: three case reports - ScienceDirect", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/pii/S092493380000403X", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com" }, { "number": 9, "title": "Differential Diagnosis Between Neuroleptic Malignant Syndrome and Catatonia - ScienceDirect", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/pii/S0924933815305150", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com" }, { "number": 10, "title": "Atypical neuroleptic malignant syndrome: A systematic review of case reports - ScienceDirect", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/abs/pii/S0163834319301070", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com" }, { "number": 11, "title": "Susceptibility to neuroleptic malignant syndrome in Parkinson’s disease", "detail": "www.neurology.org", "url": "https://www.neurology.org/doi/10.1212/WNL.52.4.777", "authors": "www.neurology.org", "host": "www.neurology.org" }, { "number": 12, "title": "A 17-Year-Old Adolescent Boy With New Altered Mental ...", "detail": "www.neurology.org", "url": "https://www.neurology.org/doi/10.1212/WNL.0000000000209709", "authors": "www.neurology.org", "host": "www.neurology.org" }, { "number": 13, "title": "Neuroleptic Prescribing and Monitoring Practices in ...", "detail": "hosppeds.aappublications.org", "url": "https://hosppeds.aappublications.org/content/8/7/410", "authors": "hosppeds.aappublications.org", "host": "hosppeds.aappublications.org" }, { "number": 14, "title": "Management of Parkinson's disease", "detail": "www.neurology.org", "url": "https://www.neurology.org/doi/10.1212/WNL.50.3_Suppl_3.S2", "authors": "www.neurology.org", "host": "www.neurology.org" }, { "number": 15, "title": "International Consensus Recommendations for the Treatment of Pediatric NMDAR Antibody Encephalitis", "detail": "www.neurology.org", "url": "https://www.neurology.org/doi/10.1212/NXI.0000000000001052", "authors": "www.neurology.org", "host": "www.neurology.org" }, { "number": 16, "title": "Evaluation and Management of Children and Adolescents ...", "detail": "pediatrics.aappublications.org", "url": "http://pediatrics.aappublications.org/content/early/2016/08/18/peds.2016-1570", "authors": "pediatrics.aappublications.org", "host": "pediatrics.aappublications.org" }, { "number": 17, "title": "An international consensus study of neuroleptic malignant syndrome diagnostic criteria using the Delphi method - PubMed", "detail": "www.ncbi.nlm.nih.gov", "url": "https://www.ncbi.nlm.nih.gov/pubmed/21733489", "authors": "www.ncbi.nlm.nih.gov", "host": "www.ncbi.nlm.nih.gov" }, { "number": 18, "title": "The Central Serotonin Syndrome: Paradigm ...", "detail": "publications.aap.org", "url": "https://publications.aap.org/pediatricsinreview/article/23/12/427/34203/Consultation-With-the-Specialist-The-Central", "authors": "publications.aap.org", "host": "publications.aap.org" }, { "number": 19, "title": "Psychoses and related disorders | Treatment summaries - BNF", "detail": "bnf.nice.org.uk", "url": "https://bnf.nice.org.uk/treatment-summaries/psychoses-and-related-disorders", "authors": "bnf.nice.org.uk", "host": "bnf.nice.org.uk" }, { "number": 20, "title": "Amitriptyline | Drug Lookup | Pediatric Care Online", "detail": "publications.aap.org", "url": "https://publications.aap.org/pediatriccare/drug-monograph/18/5410/Amitriptyline", "authors": "publications.aap.org", "host": "publications.aap.org" }, { "number": 21, "title": "An Approach to the Pharmacotherapy of Neuroleptic ... - PMC", "detail": "pmc.ncbi.nlm.nih.gov", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6386430", "authors": "pmc.ncbi.nlm.nih.gov", "host": "pmc.ncbi.nlm.nih.gov" }, { "number": 22, "title": "Emergent Treatment of Neuroleptic Malignant Syndrome Induced by Antipsychotic Monotherapy Using Dantrolene", "detail": "pmc.ncbi.nlm.nih.gov", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6366389", "authors": "pmc.ncbi.nlm.nih.gov", "host": "pmc.ncbi.nlm.nih.gov" }, { "number": 23, "title": "Management of common adverse effects of antipsychotic ...", "detail": "pmc.ncbi.nlm.nih.gov", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6127750", "authors": "pmc.ncbi.nlm.nih.gov", "host": "pmc.ncbi.nlm.nih.gov" }, { "number": 24, "title": "Drug information update. Atypical antipsychotics and neuroleptic malignant syndrome: nuances and pragmatics of the association", "detail": "pmc.ncbi.nlm.nih.gov", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC5537576", "authors": "pmc.ncbi.nlm.nih.gov", "host": "pmc.ncbi.nlm.nih.gov" } ], "editorialNote": "Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.", "citations": [ { "number": 1, "title": "This label may not be the latest approved by FDA. For current ...", "detail": "www.accessdata.fda.gov", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021999s005s008lbl.pdf", "authors": "www.accessdata.fda.gov", "host": "www.accessdata.fda.gov", "snippet": "also Boxed Warning and Warnings and Precautions (5.1)]. 5.3 Neuroleptic Malignant Syndrome A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with antipsychotic drugs, including paliperidone. Clinical manifestations of N", "score": 0.7055624 }, { "number": 2, "title": "1 This label may not be the latest approved by FDA. For ...", "detail": "www.accessdata.fda.gov", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022173s034lbl.pdf", "authors": "www.accessdata.fda.gov", "host": "www.accessdata.fda.gov", "snippet": "Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac dysrhythmia). Additional signs may include elevated creatinine phosphokinase, myoglobinuria (rhabdomy", "score": 0.5553635 }, { "number": 3, "title": "quetiapine fumarate extended-release tablets", "detail": "www.accessdata.fda.gov", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/090482Orig1s000lbl.pdf", "authors": "www.accessdata.fda.gov", "host": "www.accessdata.fda.gov", "snippet": "5.4 Neuroleptic Malignant Syndrome (NMS) A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in associa-tion with administration of antipsychotic drugs, including quetiapine. Rare cases of NMS have been reported with quetiapine. Clinica", "score": 0.38852578 }, { "number": 4, "title": "Reference ID: 2906104 - accessdata.fda.gov", "detail": "www.accessdata.fda.gov", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021999s017lbl.pdf", "authors": "www.accessdata.fda.gov", "host": "www.accessdata.fda.gov", "snippet": "clinical features consistent with the neuroleptic malignant syndrome. were excluded from premarketing clinical trials.", "score": 0.3333952 }, { "number": 5, "title": "CLOZARIL- clozapine tablet TYA Pharmaceuticals", "detail": "dailymed.nlm.nih.gov", "url": "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setId=0cf63b13-48b2-4b07-b241-617725b52f6b", "authors": "dailymed.nlm.nih.gov", "host": "dailymed.nlm.nih.gov", "snippet": "Antipsychotic drugs including CLOZARIL can cause a potentially fatal symptom complex referred to as. Neuroleptic Malignant Syndrome (NMS). Clinical", "score": 0.29055843 }, { "number": 6, "title": "Neuroleptic malignant syndrome! | The BMJ", "detail": "www.bmj.com", "url": "https://www.bmj.com/rapid-response/2011/10/30/neuroleptic-malignant-syndrome", "authors": "www.bmj.com", "host": "www.bmj.com", "snippet": "Title: Neuroleptic malignant syndrome! | The BMJ\n### Neuroleptic malignant syndrome! malignant syndrome (NMS) [1] and also have reviewed extensively relevant. In addition, subsequently updates of NMS and report of 14. are relatively the salient features of NMS. It is prudent that physicians should s", "score": 0.48674685 }, { "number": 7, "title": "Neuroleptic Malignant Syndrome - ScienceDirect", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/abs/pii/B9780125897624500839", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com", "snippet": "## Article preview. ## Primer on the Autonomic Nervous System (Second Edition). # 82- Neuroleptic Malignant Syndrome. Author links open overlay panel,. ## Publisher Summary. The neuroleptic malignant syndrome is a rare and potentially fatal syndrome of hyperthermia, rigidity, autonomic instability, ", "score": 0.82728493 }, { "number": 8, "title": "Major symptoms and differential diagnosis of neuroleptic malignant syndrome: three case reports - ScienceDirect", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/pii/S092493380000403X", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com", "snippet": "Title: Major symptoms and differential diagnosis of neuroleptic malignant syndrome: three case reports - ScienceDirect\n## European Psychiatry. # Original article Major symptoms and differential diagnosis of neuroleptic malignant syndrome: three case reports. The authors describe the cases of three p", "score": 0.784336 }, { "number": 9, "title": "Differential Diagnosis Between Neuroleptic Malignant Syndrome and Catatonia - ScienceDirect", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/pii/S0924933815305150", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com", "snippet": "Title: Differential Diagnosis Between Neuroleptic Malignant Syndrome and Catatonia - ScienceDirect\n## Article preview. ## European Psychiatry. Volume 30, Supplement 1, 28–31 March 2015, Page 652. # Article: 0652 Topic: EPW20 – e-Poster Walk Session 20: Emergency Psychiatry Differential Diagnosis Bet", "score": 0.75659186 }, { "number": 10, "title": "Atypical neuroleptic malignant syndrome: A systematic review of case reports - ScienceDirect", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/abs/pii/S0163834319301070", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com", "snippet": "Title: Atypical neuroleptic malignant syndrome: A systematic review of case reports - ScienceDirect\n# Review article Atypical neuroleptic malignant syndrome: A systematic review of case reports. Neuroleptic malignant syndrome (NMS) is a rare, idiosyncratic and potentially fatal side effect of antips", "score": 0.70263255 }, { "number": 11, "title": "Susceptibility to neuroleptic malignant syndrome in Parkinson’s disease", "detail": "www.neurology.org", "url": "https://www.neurology.org/doi/10.1212/WNL.52.4.777", "authors": "www.neurology.org", "host": "www.neurology.org", "snippet": "7. Kewal K. Jain, \n Kewal K. Jain, \n\nNeuroleptic Malignant Syndrome, Drug-induced Neurological Disorders, (575-584), (2021).\n\nCrossref\n\n8. Ana Velosa, \n António Neves, \n J Bernardo Barahona-Corrêa, \n Albino J Oliveira-Maia, \n\nNeuroleptic malignant syndrome: ", "score": 0.39662948 }, { "number": 12, "title": "A 17-Year-Old Adolescent Boy With New Altered Mental ...", "detail": "www.neurology.org", "url": "https://www.neurology.org/doi/10.1212/WNL.0000000000209709", "authors": "www.neurology.org", "host": "www.neurology.org", "snippet": "Go to Citation\n\nCrossref\n\nPubMed\n\nGoogle Scholar\n\n14.\n\nGhaziuddin N, Hendriks M, Patel P, Wachtel LE, Dhossche DM. Neuroleptic malignant syndrome/malignant catatonia in child psychiatry: literature review and a case series. _J Child Adolesc Psychopharmacol._ 2017;27(4):359-365.\n\nGo to Citation\n\nCros", "score": 0.34767053 }, { "number": 13, "title": "Neuroleptic Prescribing and Monitoring Practices in ...", "detail": "hosppeds.aappublications.org", "url": "https://hosppeds.aappublications.org/content/8/7/410", "authors": "hosppeds.aappublications.org", "host": "hosppeds.aappublications.org", "snippet": "Neuroleptic use can have significant and lasting adverse neurologic, metabolic, and cardiovascular effects. neuroleptic malignant syndrome.27", "score": 0.25714943 }, { "number": 14, "title": "Management of Parkinson's disease", "detail": "www.neurology.org", "url": "https://www.neurology.org/doi/10.1212/WNL.50.3_Suppl_3.S2", "authors": "www.neurology.org", "host": "www.neurology.org", "snippet": "Google Scholar\n\n283.\n\nStarkstein SE, Preziosi TJ, Forrester AW, Robinson RG. Specificity of affective and autonomic symptoms of depression in Parkinson's disease. _J Neurol Neurosurg Psychiatry_ 1990;_53_:869-873.\n\nGoogle Scholar\n\n284.\n\nSantamaria J, Tolosa E, Valles A. Parkinson's disease with depr", "score": 0.23625223 }, { "number": 15, "title": "International Consensus Recommendations for the Treatment of Pediatric NMDAR Antibody Encephalitis", "detail": "www.neurology.org", "url": "https://www.neurology.org/doi/10.1212/NXI.0000000000001052", "authors": "www.neurology.org", "host": "www.neurology.org", "snippet": "The Panel acknowledged that although immunotherapy is the therapeutic priority to treat the underlying disease, symptomatic management (such as antiseizure medications) is equally important (Table 3, 3.3). However, symptom management may be challenging and requires multidisciplinary expertise.e11 As", "score": 0.21755393 }, { "number": 16, "title": "Evaluation and Management of Children and Adolescents ...", "detail": "pediatrics.aappublications.org", "url": "http://pediatrics.aappublications.org/content/early/2016/08/18/peds.2016-1570", "authors": "pediatrics.aappublications.org", "host": "pediatrics.aappublications.org", "snippet": "NMS, neuroleptic malignant syndrome; This table provides suggestions for some of the most commonly used drugs for management of the agitated pediatric patient.", "score": 0.20813099 }, { "number": 17, "title": "An international consensus study of neuroleptic malignant syndrome diagnostic criteria using the Delphi method - PubMed", "detail": "www.ncbi.nlm.nih.gov", "url": "https://www.ncbi.nlm.nih.gov/pubmed/21733489", "authors": "www.ncbi.nlm.nih.gov", "host": "www.ncbi.nlm.nih.gov", "snippet": "Title: An international consensus study of neuroleptic malignant syndrome diagnostic criteria using the Delphi method - PubMed\nPhysicians Postgraduate Press, Inc. full text link. # An international consensus study of neuroleptic malignant syndrome diagnostic criteria using the Delphi method. # An in", "score": 0.76279575 }, { "number": 18, "title": "The Central Serotonin Syndrome: Paradigm ...", "detail": "publications.aap.org", "url": "https://publications.aap.org/pediatricsinreview/article/23/12/427/34203/Consultation-With-the-Specialist-The-Central", "authors": "publications.aap.org", "host": "publications.aap.org", "snippet": "by DH Arnold · 2002 · Cited by 7 — Your differential diagnosis includes toxic ingestion, infectious encephalitis, and closed-head trauma. neuroleptic malignant syndrome", "score": 0.48733237 }, { "number": 19, "title": "Psychoses and related disorders | Treatment summaries - BNF", "detail": "bnf.nice.org.uk", "url": "https://bnf.nice.org.uk/treatment-summaries/psychoses-and-related-disorders", "authors": "bnf.nice.org.uk", "host": "bnf.nice.org.uk", "snippet": "... symptoms are identified, treatment should be reviewed with ... Neuroleptic malignant syndrome (hyperthermia, fluctuating level of consciousness, muscle rigidity", "score": 0.43496582 }, { "number": 20, "title": "Amitriptyline | Drug Lookup | Pediatric Care Online", "detail": "publications.aap.org", "url": "https://publications.aap.org/pediatriccare/drug-monograph/18/5410/Amitriptyline", "authors": "publications.aap.org", "host": "publications.aap.org", "snippet": "Severe cases may cause hyperthermia, significant autonomic instability ・ blood pressure and pulse), coma, and seizures ・ neuroleptic malignant syndrome.", "score": 0.39789218 }, { "number": 21, "title": "An Approach to the Pharmacotherapy of Neuroleptic ... - PMC", "detail": "pmc.ncbi.nlm.nih.gov", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6386430", "authors": "pmc.ncbi.nlm.nih.gov", "host": "pmc.ncbi.nlm.nih.gov", "snippet": "We conducted a systematic search strategy of PubMed of the following terms: _neuroleptic malignant syndrome, treatment, therapeutics, disease management/pharmacology, disease management/therapy, dantrolene, bromocriptine, amantadine, benzodiazepines_. A total of 56 publications were identified, of w", "score": 0.7606688 }, { "number": 22, "title": "Emergent Treatment of Neuroleptic Malignant Syndrome Induced by Antipsychotic Monotherapy Using Dantrolene", "detail": "pmc.ncbi.nlm.nih.gov", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6366389", "authors": "pmc.ncbi.nlm.nih.gov", "host": "pmc.ncbi.nlm.nih.gov", "snippet": "The patient was started on an intravenous 1mg/kg bolus of dantrolene, followed by 1mg/kg intravenously every six hours in the ED. He was admitted to the ICU for close monitoring. On hospital day two, he began to show improvement in alertness and cognition but remained mostly somnolent with no improv", "score": 0.755078 }, { "number": 23, "title": "Management of common adverse effects of antipsychotic ...", "detail": "pmc.ncbi.nlm.nih.gov", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6127750", "authors": "pmc.ncbi.nlm.nih.gov", "host": "pmc.ncbi.nlm.nih.gov", "snippet": "Neuroleptic malignant syndrome is a medical emergency, often requiring intensive care. Evidence is from case reports rather than randomized clinical trials. For the psychiatrist, first steps are immediate withdrawal of all antipsychotics and related drugs (e.g., metoclopramide), cooling measures, an", "score": 0.68798697 }, { "number": 24, "title": "Drug information update. Atypical antipsychotics and neuroleptic malignant syndrome: nuances and pragmatics of the association", "detail": "pmc.ncbi.nlm.nih.gov", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC5537576", "authors": "pmc.ncbi.nlm.nih.gov", "host": "pmc.ncbi.nlm.nih.gov", "snippet": "Several pharmacological options are available for the treatment of NMS.43,44 Dopaminergic agents such as amantadine and bromocriptine have been demonstrated to decrease the duration of and mortality associated with NMS. Amantadine 200 mg to 400 mg per day in divided doses is administered either thro", "score": 0.6760432 } ], "publishedAt": "2026-08-24T18:07:24.257691+00:00", "updatedAt": "2026-08-24T18:07:24.257691+00:00", "readingMinutes": 6, "slug": "neuroleptic-malignant-syndrome" }